Prenetics Global Ltd (PRE) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown significant revenue growth and has streamlined its operations to focus on its IM8 brand, the technical indicators and trading signals do not support an immediate entry. Additionally, the stock's recent performance and lack of significant positive catalysts suggest waiting for a clearer entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 37.565, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level of 17.48, with resistance at 18.854. Overall, the technical indicators do not suggest a strong buy signal.

The company has divested non-core assets, generating $150M in proceeds and simplifying its operations. IM8, the company's focus brand, has scaled to over $100M in revenue and shows potential for growth. Analysts have given buy ratings with price targets significantly above the current price.
No significant trading trends from hedge funds or insiders. The stock has a 70% chance of declining in the short term based on historical patterns. No recent news or significant event-driven catalysts. Financials, while improving, still show negative net income and EPS.
In Q4 2025, revenue increased by 248.57% YoY to $36.56M, and gross margin improved to 59.47%. However, net income remains negative at -$28.12M, albeit improving by 72.05% YoY. EPS also remains negative at -1.75, though it has improved by 36.72% YoY.
Analysts from Lake Street and Roth Capital have initiated coverage with buy ratings and price targets of $29 and $36, respectively. They highlight the company's focus on its IM8 brand and its growth potential, which is underappreciated at current levels.